Latest treatment of multiple sclerosis Stories
WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent.
New study published in Journal of Molecular Diagnostics follows recent publication showing utility of Chronix's serum DNA tests in breast cancer.
NES-ZIONA, Israel, April 1 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc.
A cannabis-based medicine that is used in the treatment of multiple sclerosis could be approved in Spain and the UK by the second quarter of this year.
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.
WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018.
NES-ZIONA, Israel, Jan. 25 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today reported positive results from a comparative study in primates of its longer-acting version of the multiple sclerosis drug interferon beta (IFN-beta-1a-CTP, referred to as IFN-beta-CTP).
Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRIÂ® (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.
The source of PML, the JC virus, is found to be reactivated in multiple sclerosis patients receiving natalizumab treatment.
WALTHAM, Mass., Sept.